M K Proteins

Why is M K Proteins Ltd falling/rising?

As of 07-Aug, M K Proteins Ltd's stock price is experiencing a slight increase after three days of decline, indicating a potential trend reversal and heightened investor interest. However, it remains below key moving averages, suggesting ongoing bearish conditions despite today's positive performance.

As of 07-Aug, M K Proteins Ltd's stock price is rising, as indicated by a change of 0.03 (0.72%) upward. This increase comes after three consecutive days of decline, suggesting a potential trend reversal. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 29.39% compared to the 5-day average, indicating growing interest in the stock. However, it is important to note that M K Proteins is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bearish trend. Despite this, the stock's performance today aligns with the sector, and the liquidity remains sufficient for trading. Overall, the recent uptick in price can be attributed to the trend reversal and increased investor activity, despite the longer-term challenges reflected in its year-to-date and one-year performance.

Which are the latest news on M K Proteins?

When is the next results date for M K Proteins Ltd?

The next results date for M K Proteins Ltd is 13 August 2026.

The next results date for M K Proteins Ltd is scheduled for 13 August 2026.

What does M K Proteins do?

M K Proteins Ltd is a micro-cap company in the edible oil industry, incorporated in 2012 and publicly listed since 2017, with net sales of 146 Cr and a net profit of 1 Cr as of March 2026. Key financial metrics include a P/E ratio of 27.00 and a market cap of INR 182 Cr.

Overview:<BR>M K Proteins Ltd operates in the edible oil industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 2012 as "M K Proteins Private Limited" in Haryana and later converted to a public limited company, changing its name to "M K Proteins Limited" in 2017. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 146 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 182 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 27.00<BR>- Industry P/E: 27<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 9.26%<BR>- Price to Book: 2.51<BR><BR>Contact Details:<BR>Address: Naraingarh Road, Village Garnala Ambala Haryana : 134003<BR>Tel: 91-171-2679157/2679358<BR>Email: info@mkproteins.in<BR>Website: http://www.mkproteins.in

How big is M K Proteins?

No Data Available for the Stock

Who are in the management team of M K Proteins?

The management team of M K Proteins includes Vinod Kumar (Chairman & Managing Director), Raj Kumar (Whole-time Director), and several directors and independent directors, along with Prerna Mehta as Company Secretary & Compliance Officer.

The management team of M K Proteins includes the following individuals:<BR><BR>1. **Vinod Kumar** - Chairman & Managing Director<BR>2. **Raj Kumar** - Whole-time Director<BR>3. **Parvind Kumar** - Director<BR>4. **Pramod Kumar** - Director<BR>5. **Chatter Singh** - Independent Director<BR>6. **Raman Kumar Sah** - Independent Director<BR>7. **Abhay Kumar** - Independent Director<BR>8. **Dinesh Singh Malik** - Independent Director<BR>9. **Laxmi Mandal** - Independent Director<BR>10. **Prerna Mehta** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about M K Proteins or its management, feel free to ask!

Who are the peers of the M K Proteins?

M K Proteins' peers include Gokul Refoils, Evexia Lifecare, Integ. Proteins, Vijay Solvex, Ajanta Soya, Prime Industries, and Ramdevbaba Sol, with varying management risks and growth ratings. In terms of returns, Integ. Proteins leads with 222.35% over one year, while M K Proteins has a return of -34.22%.

Peers: The peers of M K Proteins are Gokul Refoils, Evexia Lifecare, Integ. Proteins, Vijay Solvex, Ajanta Soya, Prime Industries, and Ramdevbaba Sol.<BR><BR>Quality Snapshot: Excellent management risk is observed at Integ. Proteins and Vijay Solvex, while Average management risk is found at Gokul Refoils, Evexia Lifecare, Ajanta Soya, and M K Proteins, and the rest have Below Average management risk. Growth is Excellent at Prime Industries, Average at Integ. Proteins, and Below Average at Gokul Refoils, Evexia Lifecare, Vijay Solvex, Ajanta Soya, M K Proteins, and Ramdevbaba Sol. For Capital Structure, Excellent ratings are seen at Vijay Solvex, Ajanta Soya, M K Proteins, and Prime Industries, while Good is noted at Integ. Proteins, and the rest have Below Average.<BR><BR>Return Snapshot: Integ. Proteins has the highest 1-year return at 222.35%, while Ajanta Soya has the lowest at -47.09%, with M K Proteins' 1-year return at -34.22% being higher than Ajanta Soya's but lower than Integ. Proteins'. Additionally, Gokul Refoils, Evexia Lifecare, Vijay Solvex, Ajanta Soya, and Ramdevbaba Sol. all have negative six-month returns.

Should I buy, sell or hold M K Proteins Ltd?

Are M K Proteins Ltd latest results good or bad?

M K Proteins Ltd's latest results are concerning, as revenue increased by 62.95% to ₹145.94 crores, but net profit fell by 59.29% to ₹1.14 crores, indicating significant margin compression and operational challenges despite record revenue.

The latest results for M K Proteins Ltd indicate a challenging situation for the company. While the revenue for Q4 FY26 showed a significant increase of 62.95% quarter-on-quarter, reaching ₹145.94 crores, the net profit plummeted by 59.29% both quarter-on-quarter and year-on-year, down to ₹1.14 crores. This stark contrast highlights a troubling disconnect between revenue growth and profitability.<BR><BR>The operating margin also fell sharply to 1.71%, down from 2.65% in the previous quarter, marking a significant decline in operational efficiency. Additionally, the PAT margin dropped to 0.78%, the lowest in several quarters. This suggests that the company is facing severe margin compression, likely due to rising costs and competitive pressures in the edible oil sector.<BR><BR>Overall, despite achieving record revenue, the substantial drop in profitability and margins indicates that the results are more concerning than positive. Investors may view these developments as a signal of underlying operational challenges that need to be addressed for future growth and stability.

How has been the historical performance of M K Proteins?

M K Proteins' historical performance shows fluctuating revenue, with net sales increasing to 267.71 Cr in March 2025 from 245.57 Cr in March 2024, but declining from 314.86 Cr in March 2023. Profitability decreased, with operating profit falling to 12.43 Cr and cash flow showing a negative trend, indicating challenges in profitability and cash management despite some sales growth.

Answer:<BR>The historical performance of M K Proteins shows fluctuations in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>M K Proteins reported net sales of 267.71 Cr in March 2025, an increase from 245.57 Cr in March 2024, but a decline from 314.86 Cr in March 2023. The total operating income followed a similar trend, reaching 267.71 Cr in March 2025 compared to 245.57 Cr in the previous year. The company's total expenditure, excluding depreciation, was 255.28 Cr in March 2025, up from 228.95 Cr in March 2024. Operating profit, excluding other income, decreased to 12.43 Cr in March 2025 from 16.62 Cr in March 2024, leading to an operating profit margin of 4.64%. Profit before tax also declined to 11.45 Cr in March 2025 from 15.47 Cr in March 2024, resulting in a profit after tax of 8.40 Cr. The company's total assets increased to 130.23 Cr in March 2025 from 95.87 Cr in March 2024, while total liabilities rose to 130.23 Cr from 95.87 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 16.00 Cr in March 2025, contrasting with a positive inflow of 32.00 Cr in March 2024. Overall, M K Proteins experienced a mixed performance with some growth in sales but challenges in profitability and cash flow management.

Is M K Proteins overvalued or undervalued?

As of November 19, 2025, M K Proteins is considered very attractive and undervalued, with a PE ratio of 28.91, an EV to EBITDA of 18.57, and a ROCE of 17.66%, making it a compelling investment opportunity despite a year-to-date return of -20.34%.

As of 19 November 2025, the valuation grade for M K Proteins has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 28.91, an EV to EBITDA of 18.57, and a ROCE of 17.66%. <BR><BR>In comparison to its peers, M K Proteins has a significantly lower PE ratio than Manorama Industries, which stands at 45.44, and a more favorable EV to EBITDA ratio than CIAN Agro, which is at 16.34. Despite recent underperformance, with a year-to-date return of -20.34% compared to the Sensex's 9.02%, the strong valuation metrics suggest that M K Proteins presents a compelling investment opportunity.

Who are the top shareholders of the M K Proteins?

The top shareholders of M K Proteins are primarily promoters, with Pragun Garg holding the largest individual stake at 6.33%. Individual investors collectively own 21.6% of the shares, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of M K Proteins primarily consist of the promoters, with Pragun Garg holding the highest individual stake at 6.33%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, individual investors collectively hold 21.6% of the company's shares.

What is the technical trend for M K Proteins?

As of May 12, 2025, M K Proteins shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and Bollinger Bands, but daily moving averages indicating caution.

As of 12 May 2025, the technical trend for M K Proteins has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the daily moving averages indicate a mildly bearish stance. The Bollinger Bands on the weekly chart are also mildly bullish, contrasting with the monthly view which is bearish. The KST shows a mildly bullish trend on the weekly timeframe, and Dow Theory supports a mildly bullish outlook as well. However, the overall sentiment remains cautious due to the daily moving averages and the lack of strong signals from the RSI and OBV. The current technical stance is mildly bearish, reflecting mixed signals across different indicators.

What is the bonus history of the M K Proteins?

M K Proteins has a history of issuing bonuses, with the latest being a 2:1 bonus announced for March 15, 2024, following another 2:1 bonus on February 3, 2023. This demonstrates the company's commitment to rewarding its shareholders.

M K Proteins has a history of issuing bonuses, with the most recent being a 2:1 bonus issue announced for March 15, 2024. Prior to that, the company also issued a 2:1 bonus on February 3, 2023. This consistent approach to bonus issues reflects the company's strategy to reward its shareholders. If you have any more questions about M K Proteins or need further details, feel free to ask!

Has M K Proteins declared dividend?

No Dividend History Available